Participate in a Clinical Trial

Without the participation of people with MS, it would be impossible to develop new and better therapies and other interventions.

Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation

Study Purpose

Multiple Sclerosis (MS) is an inflammatory disease where the immune cells invade the central nervous system and destroy an essential element of nerve conduction: the myelin. An interesting feature observed in some patients is a regenerative process, called remyelination, which leads to the production of new myelin. However, the extent of remyelination is very heterogeneous among patients, only a minority of patients show a really efficient repair process along the disease course. In this project, our aim is to explore in vivo the biological mechanisms leading to a successful remyelination in some patients and to a failure in remyelination in others. With this purpose in mind we propose to develop a translational research platform where patients with multiple sclerosis will be investigated in vivo for their potential of remyelination through a follow-up with recently developed imaging technologies using a synergistic combination of magnetic resonance imaging (MRI) and positron emission tomography (PET) to visualize and quantify myelin and neuroinflammation. In parallel blood immune cells from patients will be sampled and profiled to investigate how they could influence remyelination. This part will consist in i) grafting patients' lymphocytes in experimental rodent models of demyelination to characterize how they could promote or inhibit remyelination; ii) performing a functional and multi-omics analysis of peripheral macrophages and analyse relationships with remyelination profiles; iii) profiling T lymphocytes at the single cell level to associate specific subpopulation of the T cells with the remyelination potential assessed in patients with MRI/PET images and in grafted animals.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Yes
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Interventional
Eligible Ages	18 Years - 55 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

RRMS patients: 1. Age between 18 and 55 years old. 2. RRMS according to the 2017 Mc Donald criteria. 3. Less than 5 years of disease duration. 4. At least 9 supra-tentorial white matter lesions on T2/FLAIR MRI. 5. Last treatment with methylprednisolone should have been performed at least 1 month before PET examinations. 6. Interferon-beta, glatiramere acetate and oral first line therapy will such as dimethylfumarate or teriflunomide will be admitted. 7. Affiliation to a social security scheme or beneficiary of such a scheme (Except "Aide Médicale d'Etat") Progressive MS patients: 1. Age between 18 and 55 years old. 2. Progressive MS (primary or secondary progressive MS) according to the 2017 Mc Donald criteria. 3. Less than 10 years of disease duration in the progressive phase. 4. At least 9 supra-tentorial white matter lesions on T2/FLAIR MRI. 5. Interferon-beta, glatiramere acetate and oral first line therapy will such as dimethylfumarate or teriflunomide will be admitted. 6. Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat") Healthy volunteers: 1. Age between 18 and 55 years old. 2. Without any evolutive pathology. 3. Able to understand the study objectives and procedures. 4. Affiliation to a social security scheme or beneficiary of such a scheme (except "Aide Médicale d'Etat")

Exclusion Criteria:

For all participants: 1. Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace maker or the presence of an intra-ocular foreign body (a contra-indication questionnaire will be filled in beforehand) 2. PET for clinical research already done within the last 12 months. 3. Low Affinity Binding profile (TSPO polymorphism analyzed at screening visit) 4. Pregnancy, breast-feeding, lack of efficient contraception. 5. Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases. 6. Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly) 7. Know hypersensitivity to Myelin PET : [18F]-Florbetaben. 8. Patient under legal protection. Additional exclusion criteria for patients: 1. Treatment with cyclophosphamide, mitoxantrone, fingolimod, cladribine, alemtuzumab, anti CD20 antibodies or natalizumab will not be admitted. These treatments may be administered after the Baseline visit. 2. Known allergy to gadoteric acid. 3. Allergies (seafood, pollinosis, urticarial) having required a medical intervention. 4. Severe renal insufficiency (creatinine clearance < 60mL/min).

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT05147532
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.	N/A
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Assistance Publique - Hôpitaux de Paris
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Recruiting
Countries	France
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Multiple Sclerosis, Inflammatory Disease

Arms & Interventions

Arms

Other: PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714

PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714

Interventions

Procedure: - PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714

PET-MRI: 2 at baseline visits (V0 and V1) and 1 at M6

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Paris, France

Status

Recruiting

Address

CIC Neurosciences - Hôpital Pitié Salpêtrière

Paris, , 75013

Site Contact

Céline LOUAPRE, MD

[email protected]

0171970659

Clinical Trials in MS

The latest clinical research in MS, including trials funded by the Society and trials in progressive MS.

NARCOMS Patient Registry

Register as a willing MS research participant to facilitate multicenter studies. Initiated by the Consortium of MS Centers.

Visit NARCOMS

Posting a Trial

If you would like us to post a study on these pages, please email [email protected] to find out what information you need to submit for review.

Clinical Trial Finder